Emerging Stocks Down Under 4 January 2022: Pharmaxis, 8Common, Peppermint Innovation
Pharmaxis: It's all about the news flowIn today's edition of Emerging Stocks Down Under, headquartered in the Northern Sydney suburb of Frenchs Forest, Pharmaxis is an early-stage drug developer at its core. The thing that sets Pharmaxis apart from other companies in this stage of development is the two products approved and making their way through global distribution channels. To be clear, Pharmaxis is not yet profitable, but it is on its way after these two products saw strong approval and distribution growth in FY21.It seems likely shareholders will be in for further dilution, though, despite the one year of financial runway the company had as of 30 June 2021. Yet, at its current valuation, we believe the rewards far outweigh the risk. Also in today's edition, a look at software developer 8Common (ASX: 8CO) and remittance and digital payments services Peppermint Innovation (ASX: PIL).
Click here to read the previous edition of Emerging Stocks Down Under published 21 December 2021
Please register or upgrade your plan to access this content.